NCT07305337 Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
| NCT ID | NCT07305337 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongnan Hospital |
| Condition | Leukaemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 196 participants |
| Start Date | 2025-06-28 |
| Primary Completion | 2026-08-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 196 participants in total. It began in 2025-06-28 with a primary completion date of 2026-08-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With the rapid advancement of biopharmaceutical technology, clinical trials have become the crucial bridge connecting new drugs from the laboratory to clinical application. Despite the increasing number of clinical trial projects being conducted, nearly all such projects face the common challenge of recruitment difficulties. Subject recruitment constitutes a pivotal stage in clinical trials; the ability to recruit a sufficient number of subjects meeting the trial requirements significantly impacts trial quality and also serves as a key factor influencing trial progress. Hematologic cancers constitute a highly heterogeneous group of malignant diseases originating in the haematopoietic organs and primarily affecting the haematopoietic system. They encompass acute and chronic leukaemias, malignant lymphomas, multiple myeloma, myelodysplastic syndromes, and related disorders. For patients facing treatment decisions, clinical trials represent not only a vital avenue for accessing cutting-edge therapies but also impose heightened demands on their capacity for informed decision-making. Conversational artificial intelligence (AI) based on large language models is rapidly advancing in health education and public health communication. Medical chatbots offer scalable and personalised advantages in delivering health information, promoting behavioural change, and enhancing patient engagement, providing a viable pathway for improving trial literacy and decision support. Accordingly, this study proposes to conduct a clinical trial literacy intervention using AI-powered chatbots among haematological malignancy patients. Through a randomised controlled trial (RCT), it aims to evaluate the impact of AI-assisted health education on patients' understanding of clinical trials and intention to participate. This research seeks to validate the application value of AI technology in health education and explore scalable AI-assisted health education intervention models.
Eligibility Criteria
Inclusion Criteria (1) Aged ≥18 years with clear consciousness; (2) Diagnosed with haematological malignancy meeting clinical treatment criteria (WHO criteria); (3) Capable of understanding health education content and possessing basic communication skills; (4) Willing to participate in this study and sign an informed consent form. Exclusion Criteria (1) Patients with concomitant cognitive impairment, psychiatric disorders, or other conditions severely affecting comprehension; (2) Anticipated hospital stay of less than 3 days, rendering completion of the intervention unfeasible; (3) End-of-life palliative care; (4) Previous participation in other clinical trial education programmes.
Contact & Investigator
Fuling Fu Zhou
STUDY DIRECTOR
Zhongnan Hospital of Wuhan Universty
Frequently Asked Questions
Who can join the NCT07305337 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Leukaemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07305337 currently recruiting?
Yes, NCT07305337 is actively recruiting participants. Contact the research team at zhoufuling@163.com.cn for enrollment information.
Where is the NCT07305337 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07305337 clinical trial?
NCT07305337 is sponsored by Zhongnan Hospital. The principal investigator is Fuling Fu Zhou at Zhongnan Hospital of Wuhan Universty. The trial plans to enroll 196 participants.